CCR5 and neoplasm: To understand the cause of CCL5-mediated reduced survival in PDAC, we hypothesized that immune cells responsive to a CCL5 chemotactic gradient (through expression of the cognate receptors CCR5, CCR3, or CCR1) could be potential contributors to an adverse tumor immune environment (Figure 1B, Figure 1—figure supplement 1A).